## Poulikos I Poulikakos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/512880/publications.pdf

Version: 2024-02-01

24 papers 2,882 citations

394421 19 h-index 713466 21 g-index

24 all docs

24 docs citations

times ranked

24

5910 citing authors

#	Article	IF	CITATIONS
1	Targeting RAS–ERK signalling in cancer: promises and challenges. Nature Reviews Drug Discovery, 2014, 13, 928-942.	46.4	887
2	BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell, 2015, 28, 370-383.	16.8	392
3	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood, 2014, 124, 3007-3015.	1.4	352
4	New perspectives for targeting RAF kinase in human cancer. Nature Reviews Cancer, 2017, 17, 676-691.	28.4	285
5	SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Reports, 2019, 26, 65-78.e5.	6.4	146
6	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell, 2016, 30, 485-498.	16.8	130
7	Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. Blood, 2016, 128, 2533-2537.	1.4	122
8	Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research, 2016, 22, 1592-1602.	7.0	108
9	Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nature Communications, 2015, 6, 7103.	12.8	100
10	RAF/MEK/extracellular signal–related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. Journal of Experimental Medicine, 2018, 215, 319-336.	8.5	58
11	Inhibitors of BRAF dimers using an allosteric site. Nature Communications, 2020, 11, 4370.	12.8	48
12	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nature Medicine, 2021, 27, 851-861.	30.7	38
13	Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. Clinical Cancer Research, 2022, 28, 4618-4628.	7.0	37
14	AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. Cancer Discovery, 2021, 11, 3064-3089.	9.4	32
15	ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation. Nature Communications, 2022, 13, 703.	12.8	31
16	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery, 2021, 11, 1716-1735.	9.4	30
17	Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nature Cancer, 2021, 2, 429-443.	13.2	29
18	Activating <i>MAPK1</i> (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget, 2017, 8, 46065-46070.	1.8	24

#	Article	IF	CITATIONS
19	Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. Oncogene, 2019, 38, 47-59.	5.9	20
20	Global view of the RAF-MEK-ERK module and its immediate downstream effectors. Scientific Reports, 2019, 9, 10865.	3.3	12
21	A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer Journal of Clinical Oncology, 2018, 36, TPS1103-TPS1103.	1.6	1
22	Abstract 41: Tumor resistance to CDK4/6 inhibitors and degraders determined by the expression state of CDK6. , 2021, , .		0
23	Reconstructing the Clonal and Mutational Architecture of Myeloma through Avian Leukosis Virus (ALV)-Mediated Genome Editing. Blood, 2018, 132, 4480-4480.	1.4	O
24	Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone. Blood, 2021, 138, 4720-4720.	1.4	0